ECTRIMS data show long-term impact of Ocrevus in MS

13 October 2021
2020_roche_big

In multiple sclerosis (MS), new data for Ocrevus (ocrelizumab) should help physicians understand the long-term characteristics of treatment with the monoclonal antibody.

First approved in the USA in 2017, Roche’s (ROG: SIX) blockbuster biologic took in over $4.5 billion sales last year, up by a quarter from the year before.

It is the first and only therapy approved for both relapsing MS (RMS) and primary progressive MS (PPMS), with six-month dosing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology